1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Biomarcadores y Abordaje Personalizado del Cáncer (BioPAC)

Biomarcadores y Abordaje Personalizado del Cáncer (BioPAC)

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Abal-Sanisidro M, Palencia-Campos A, Ruiz-Cañas L, García-Fernández J, Cañada-García L, Batres-Ramos S, López-López R, Moreno R, Martín-Pastor M, Sainz B Jr, de la Fuente M.

    Biocompatible self-illuminating sphingomyelin nanosystems for photodynamic-based cancer therapy.

    J CONTROL RELEASE . 385: 113982-113982.

    [doi:10.1016/j.jconrel.2025.113982]

  • Parejo-Alonso B, Barneda D, Trabulo SMD, Courtois S, Compte-Sancerni S, Zurkovic J, Ruiz-Cañas L, Zheng Q, Tang J, Gaida MM, Schmitz U, Irun P, Penin-Peyta L, Crusz SM, Jagušt P, Espiau-Romera P, Royo-García A, Gordo-Ortiz A, Yuneva M, Lin ML, Huang S, Yang MH, Lanas A, Sainz B Jr, Thiele C, Heeschen C, Sancho P.

    PPARd Orchestrates a Prometastatic Metabolic Response to Microenvironmental Cues in Pancreatic Cancer.

    CANCER RESEARCH . 85(17): 3275-3291.

    [doi:10.1158/0008-5472.CAN-24-3475]

  • Melones-Herrero J, Aguilar-Rico F, Matesanz AI, Calés C, Sánchez-Pérez I, Quiroga AG.

    Antiproliferative activity in breast cancer cells of PtL(2): A steroid-thiosemicarbazone platinum(II) complex.

    JOURNAL OF INORGANIC BIOCHEMISTRY . 270: 112923-112923.

    [doi:10.1016/j.jinorgbio.2025.112923]

  • Cave DD, Di Domenico A, Fantuz M, Ciotola M, Mangini M, Buonaiuto S, Corrado B, Corona M, Saracino F, Andolfi G, Di Biase I, Cucciardi A, Carrer A, Sainz B Jr, Pirozzi T, Re DL, Colonna V, Minchiotti G, De Luca AC, Lonardo E.

    TGF-ß1-mediated downregulation of L1CAM in pancreatic ductal adenocarcinoma drives upregulation of collagen 17A1 and MMP2, facilitating tumor invasiveness and metastasis.

    CELL DEATH & DISEASE . 16(1): 592-592.

    [doi:10.1038/s41419-025-07859-8]

  • Vaz-Salgado MA, Sepulveda JM, Earl J, Gutierrez J, Ruano Y, Pian H, Cantero D, Hernández-Lain A.

    Oligodendrogliomas: findings after classifying the same cohort using pre- and post-World Health Organization (WHO) 2021 criteria.

    Brain Communications . 7(4): .

    [doi:10.1093/braincomms/fcaf265]

  • Earl J, Kataki A, Canzian F, Costello E, Campa D, Greenhalf W.

    Targeting pancreatic cancer screening by identification of pathogenic variants of BRCA2/ BRCA1 in healthy individuals who have no known family history of pancreatic cancer: The arguments for and against.

    Seminars in cancer biology . 113: 1-8.

    [doi:10.1016/j.semcancer.2025.05.001]

  • He J, Alhamwe BA, Sabroso S, Carrato A, Hidalgo M, Molero X, Iglesias M, Perea J, Farré A, Tardón A, Dominguez-Muñoz E, Barberà V, Muñoz-Bellvís L, Löhr M, Greenhalf W, O'Rorke M, Gress T, Crnogorac-Jurcevic T, Gayà A, Langtry A, Kleeff J, Lawlor R, Real FX, Renz H, Malats N.

    Low type-2 immune effectors modulate atopic diseases' protective role in pancreatic cancer risk.

    INTERNATIONAL JOURNAL OF CANCER . 157(3): 468-479.

    [doi:10.1002/ijc.35397]

  • Earl J.

    A plasma-based multimetabolite biomarker for early detection of pancreatic cancer.

    LANCET GASTROENTEROLOGY & HEPATOLOGY . 10(7): 607-609.

    [doi:10.1016/S2468-1253(25)00089-5]

  • Niedra H, Rogoza O, Saksis R, Peculis R, Halilova A, Gerina A, Vilisova S, Senterjakova N, Pukitis A, Ruz-Caracuel I, Earl J, Kolnikova G, Dubovan P, Tomas M, Makovicky P, Urbanova M, Smolkova B, Koniaris E, Aggelioudaki I, Kataki A, Rovite V.

    Transcriptomic profiling of pancreatic neuroendocrine tumors: dysregulation of WNT, MAPK, PI3K, neddylation pathways and potential non-invasive biomarkers.

    Plos One . 20(6): .

    [doi:10.1371/journal.pone.0325672]

  • Raposeiras-Roubin S, Amat-Santos IJ, Rossello X, González Ferreiro R, González Bermúdez I, Lopez Otero D, Nombela-Franco L, Gheorghe L, Diez JL, Baladrón Zorita C, Baz JA, Muñoz García AJ, Vilalta V, Ojeda-Pineda S, de la Torre Hernández JM, Cordoba Soriano JG, Regueiro A, Bordes Siscar P, Salgado Fernández J, Garcia Del Blanco B, Martín-Reyes R, Romaguera R, Moris C, García Blas S, Franco-Peláez JA, Cruz-González I, Arzamendi D, Romero Rodríguez N, Díez-Del Hoyo F, Camacho Freire S, Bosa Ojeda F, Astorga Burgo JC, Molina Navarro E, Caballero Borrego J, Ruiz Quevedo V, Sánchez-Recalde Á, Peral Disdier V, Alegría-Barrero E, Torres-Llergo J, Feltes G, Fernández Díaz JA, Cuellas C, Jiménez Britez G, Sánchez-Rubio Lezcano J, Barreiro-Pardal C, Núñez-Gil I, Abu-Assi E, Iñiguez-Romo A, Fuster V, Ibáñez B.

    Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation.

    NEW ENGLAND JOURNAL OF MEDICINE . 392(14): 1396-1405.

    [doi:10.1056/NEJMoa2500366]

  • Hewitt E, Bouche G, Alencar AC, Bigelsen SJ, Radu R, Stoyanova-Beninska V, Carrato A, Valsecchi F, Soler Cantón A, van der Meer HG, García Bermejo ML, Budillon A, Cardone L, Rooman I, Platteeuw H, Baijet J, Fuchs C.

    Drug Repurposing in Pancreatic Cancer: A Multi-Stakeholder Perspective to Improve Treatment Options for Pancreatic Cancer Patients.

    Cancer Management And Research . 17: 429-440.

    [doi:10.2147/CMAR.S483151]

  • Marabelle A, O'Malley DM, Hendifar AE, Ascierto PA, Motola-Kuba D, Penel N, Cassier PA, Bariani G, De Jesus-Acosta A, Doi T, Longo F, Miller WH Jr, Oh DY, Gottfried M, Yao L, Jin F, Gozman A, Maio M.

    Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial.

    Nature Cancer . 6(2): 253-258.

    [doi:10.1038/s43018-024-00894-y]

  • Tost J, Ak-Aksoy S, Campa D, Corradi C, Farinella R, Ibáñez-Costa A, Dubrot J, Earl J, Melian EB, Kataki A, Kolnikova G, Madjarov G, Chaushevska M, Strnadel J, Tanic M, Tomas M, Dubovan P, Urbanova M, Buocikova V, Smolkova B.

    Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications.

    Seminars in cancer biology . 109: 101-124.

    [doi:10.1016/j.semcancer.2025.01.003]

  • Bakirdögen D, Görgülü K, Xin J, Alcalá S, Ruiz-Cañas L, Frank K, Wu N, Diakopoulos KN, Dai C, Öztürk H, Demircioglu D, Peschke K, Ranjan R, Fusco F, Martinez-Useros J, Fernandez-Aceñero MJ, Chhabra NF, López-Gil JC, Ai J, Ruess DA, Kaya-Aksoy E, Steiger K, Schmidt F, Kohlmann L, Berninger A, Schmid RM, Reichert M, Adli M, Lesina M, Sainz B Jr, Algül H.

    c-Rel drives pancreatic cancer metastasis through Fibronectin-Integrin signaling-induced isolation stress resistance and EMT activation.

    Biorxiv : The Preprint Server For Biology . : .

    [doi:10.1101/2025.01.29.635445]

  • Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, Grob JJ, Lewis KD, Ansstas G, Day F, Ladwa R, Stein BN, Muñoz Couselo E, Meier F, Hauschild A, Schadendorf D, Basset-Seguin N, Modi B, Dalac-Rat S, Dunn LA, Flatz L, Mortier L, Guégan S, Heinzerling LM, Mehnert JM, Trabelsi S, Soria-Rivas A, Stratigos AJ, Ulrich C, Wong DJ, Beylot-Barry M, Bossi P, Bugés Sánchez C, Chandra S, Robert C, Russell JS, Silk AW, Booth J, Yoo SY, Seebach F, Lowy I, Fury MG, Rischin D.

    A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of Groups 1, 2, and 3, and primary analysis of fixed-dose treatment Group 6.

    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY . 92(1): 68-77.

    [doi:10.1016/j.jaad.2024.06.108]

  • Candel FJ, Salavert M, Cantón R, Del Pozo JL, Galán-Sánchez F, Navarro D, Rodríguez A, Rodríguez JC, Rodríguez-Aguirregabiria M, Suberviola B, Zaragoza R.

    The role of rapid multiplex molecular syndromic panels in the clinical management of infections in critically ill patients: an experts-opinion document.

    CRITICAL CARE . 28(1): 440-440.

    [doi:10.1186/s13054-024-05224-3]

  • Aksoy SA, Earl J, Grahovac J, Karakas D, Lencioni G, Sigirli S, Bijlsma MF.

    Organoids, tissue slices and organotypic cultures: Advancing our understanding of pancreatic ductal adenocarcinoma through in vitro and ex vivo models.

    Seminars in cancer biology . 109: 10-24.

    [doi:10.1016/j.semcancer.2024.12.003]

  • Palencia-Campos A, Ruiz-Cañas L, Abal-Sanisidro M, López-Gil JC, Batres-Ramos S, Saraiva SM, Yagüe B, Navarro D, Alcalá S, Rubiolo JA, Bidan N, Sánchez L, Mura S, Hermann PC, de la Fuente M, Sainz B.

    Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasis.

    JOURNAL OF NANOBIOTECHNOLOGY . 22(1): 795-795.

    [doi:10.1186/s12951-024-03010-5]